Announced Wed, 12 Aug · 17:09 IST
Hikal Q1 FY27 call: guides 14-16% revenue growth, 25-30% EBITDA growth
Mgmt Guided Margin ImprovementMgmt Guided Margin PressureOrder Pipeline DisclosedCfo Debt Reduction RoadmapInvestor Communications View source PDFExplain this filing
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.7%1-day move
₹211.95
prior close
₹212.84
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.1+0.1-0.5+3.7+0.5+2.2+0.9-0.1—————
Up moveDown movePending
AI summary
Q1 FY27 revenue at Rs 403 cr, EBITDA margin 9.2%, PAT at Rs -7 cr. Pharma Rs 233 cr EBIT at 3.2% margin, Crop Rs 170 cr EBIT at -6. Guides 14-16% revenue growth and 25-30% EBITDA growth for FY27. Animal Health targets Rs 400 cr by FY30, Personal Care Rs 200 cr in 3 years, both at 20% plus EBITDA margins. Net debt cut from Rs 815 cr to Rs 685 cr. US FDA re-inspection expected by year-end.
Likely market impact
Positive outlook with margin expansion as FDA remediation completes. Pharma and Animal Health to drive growth, crop remains weak.